Evidence map›Paper›PMID 31254190›Full record

Trial reportAIDS and behavior2020

Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms.

R Weinrib, E N Browne, M K Shapley-Quinn, A van der Straten, M Beksinska, N Mgodi, P Musara, N Mphili, J L Schwartz, S Ju and 3 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

R WeinribWomen's Global Health Imperative, RTI International, San Francisco, CA, USA. rweinrib@rti.org.ORCID http://orcid.org/0000-0002-7753-0996
E N BrowneWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
M K Shapley-QuinnWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
A van der StratenWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
M BeksinskaMatCH Research Unit, Department of Obstetrics and Gynaecology, School of Clinical Sciences, University of the Witwatersrand, Durban, South Africa.
N MgodiUniversity of Zimbabwe College of Health Sciences-Clinical Trials Research Centre, Harare, Zimbabwe.
P MusaraUniversity of Zimbabwe College of Health Sciences-Clinical Trials Research Centre, Harare, Zimbabwe.
N MphiliMatCH Research Unit, Department of Obstetrics and Gynaecology, School of Clinical Sciences, University of the Witwatersrand, Durban, South Africa.
J L SchwartzEastern Virginia Medical School, CONRAD, Arlington, VA, USA.
S JuEastern Virginia Medical School, CONRAD, Arlington, VA, USA.
H HanifEastern Virginia Medical School, CONRAD, Arlington, VA, USA.
E T MontgomeryWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
Quatro Study Team
RTI International · USEastern Virginia Medical School · USUniversity of Zimbabwe · ZW

Funding

Bill and Melinda Gates Foundation GSB-S-15-001EPA EP-C-15-001United States Agency for International Development AID-OAA-A-14-00010
6 · The paper itself

Abstract

introductionIncorporating end-user input into the design of new vaginal microbicides for women is key to optimizing their uptake, consistent use, and, ultimately, success in combatting the heterosexual HIV epidemic.

methodsThe Quatro Study assessed four placebo forms of vaginally inserted HIV-microbicides among young microbicide-naïve African women: on-demand film, insert and gel, and monthly ring. Participants randomly used each product for 1 month and provided product satisfaction ratings (1-5 scale), and opinions on product attributes and potential alternative designs. Qualitative data were collected through focus group discussions at study exit. Multivariable associations between attribute opinions and overall product rating were examined using Poisson regression models with robust standard errors to assess the attributes most influential to satisfaction.

resultsOverall opinions of products and their individual attributes were generally positive; all products were rated either 4 or a 5 by ≥ 50% of participants. Attributes related to ease of use and interference with normal activities were the most salient predictors of satisfaction. Preferences for duration of use tended toward relatively shorter use periods for the ring (i.e., 1-3 months vs. 12 months) and for coitally independent dosing for the on-demand products.

conclusionsHow well a product fit in with participants' lifestyles was important to their overall satisfaction. For on-demand products, greater flexibility around timing of use was desired, to avoid coital dependency of the dosing.

Indexed as

Patient Acceptance of Health CareAdministration, IntravaginalAdultAnti-Infective AgentsBlack PeopleCoitusContraceptionContraceptive AgentsCross-Over StudiesFemaleFocus GroupsHIV InfectionsHumansPre-Exposure ProphylaxisQualitative ResearchSexually Transmitted DiseasesAnti-Infective AgentsContraceptive AgentsVaginal Creams, Foams, and JelliesAcceptabilityAfricaAfrican womenEnd-user researchHIV preventionMicrobicidesProduct attributes

Identifiers

PMID31254190
PMCPMC6988116
OpenAlexW2955415147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.